OIPE JC81
JUN 10 2005
PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2

Application Number	10/680,160
Filing Date	October 8, 2003
First Named Inventor	David M. Goldenberg
Art Unit	1644
Examiner Name	HUYNH, Phuong N.
Attorney Docket Number	40923-0047 US9 [1236] (IMM 120)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
PNK	B20	FITZGERALD et al., "A Monoclonal Antibody-Pseudomonas Toxin Conjugate That Specifically Kills Multi-drug Resistant Cells", *Proc. Natl. Acad. Sci. USA*, Vol;. 84, pp. 4288-4292, June 1987, Medical Sciences.

Examiner Signature		Date Considered	8/31/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 C.F.R. 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions by reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned
				Filing Date	09/30/2003
Date Submitted: September 29, 2003				First Named Inventor	David M. GOLDENBERG
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	2	of	82	Attorney Docket Number	018733-1236

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
PNK	B18	EFFERTH et al., "Antibody-Directed Therapy of Multidrug-Resistant Tumor Cells," Med. Oncol. & Tumor Pharmacother. (1992), 9(1)11-19.	
	B19	ENDICOTT et al., "The Biochemistry of P-Glycoprotein-Mediated Multidrug Resistance," Annu. Rev. Biochem. (1989) 58:137-171.	
	B20	FITZGERALD et al., "A Monoclonal Antibody-Pseudomonas Toxin Conjugate That Specifically Kills Multidrug-Resistant Cells.	
	B21	GEORGES et al., "Modulation of ATP and Drug Binding By Monoclonal Antibodies Against P-Glycoprotein," J. Cell Physiol. (1991), 148:479-484.	
	B22	GOLDSTEIN et al., "Expression of a Multidrug Resistance Gene in Human Cancers," J. Natl. Cancer Inst. (January 18, 1989), 81:116-124.	
	B23	GRINIUS et al., "A Staphylococcal Multidrug Resistance Gene Product is a Member of a New Protein Family," Plasmid (1992), 27:119-129.	
	B24	HAMADA et al., "Functional Role for the 170- to 180-kDa Glycoprotein Specific to Drug-Resistant Tumor Cells As Revealed by Monoclonal Antibodies," Proc. Natl. Acad. Sci. USA (October 1986) 83:7785-7789.	
	B25	IWAHASHI et al., "Specific Targeting and Killing Activities of Anti-P-Glycoprotein Monoclonal Antibody MRK 16 Directed Against Intrinsically Multidrug-Resistant Human Colorectal Carcinoma Cell Lines in the Nude Mouse Model," Cancer Research (November 15, 1993), 53:5475-5482.	
	B26	NEYFAKH et al., "Efflux-Mediated Multidrug Resistance in Bacillus Subtilis: Similarities and Dissimilarities With the Mammalian System," Proc. Natl. Acad. Sci. USA (June 1991), 88:4781-4785.	
	B27	NOONAN et al., "Quantitative Analysis of MDR1 (multidrug resistance) Gene Expression in Human Tumors By Polymerase Chain Reaction," Proc. Natl. Acad. Sci. USA (September 1990), 87:7160-7164.	
	B28	PEARSON et al., "Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by in Vivo Administration of MRK-16 Monoclonal Antibody," J. Natl. Cancer Inst. (1991) 83:1386-1391.	
	B29	RITTMANN-GRAUER et al., " Reversal of Finca Alkaloid Resistance by Anti-Glycoprotein Monoclonal Antibody HYB-241 in a Human Tumor Xenograft," Cancer Res. (April 1, 1992), 52:1810-1816.	
	B30	SARKADI et al., "Interaction of Bioactive Hydrophobic Peptides With the Human Multidrug Transporter," The FASEB Journal (July 1994), 8:766:770.	
↓	B31	SCHNEIDER et al., "P-Glycoprotein Expression in Treated and Untreated Human Breast Cancer," Br. J. Cancer (1989), 60:815-818.	

Examiner Signature		Date Considered	8/31/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on